A long-term, open-label, and single-arm study of NRP104 30 mg, 50 mg, or 70 mg per day in adults with attention deficit hyperactivity disorder (ADHD).

Trial Profile

A long-term, open-label, and single-arm study of NRP104 30 mg, 50 mg, or 70 mg per day in adults with attention deficit hyperactivity disorder (ADHD).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors New River Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2009 Actual patient number (349) added as reported by ClinicalTrials.gov.
    • 03 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
    • 07 Nov 2007 Shire Pharmaceuticals Group reported as sponsor.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top